A survey of current clinical practice of permanent prostate brachytherapy in the United States

被引:83
作者
Prestidge, BR [1 ]
Prete, JJ [1 ]
Buchholz, TA [1 ]
Friedland, JL [1 ]
Stock, RG [1 ]
Grimm, PD [1 ]
Bice, WS [1 ]
机构
[1] Wilford Hall USAF Med Ctr, Radiat Oncol PSRT, Dept Radiat Oncol, Lackland AFB, TX 78236 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 1998年 / 40卷 / 02期
关键词
prostate brachytherapy; clinical practice; survey;
D O I
10.1016/S0360-3016(97)00715-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To help establish standards of care for transperineal interstitial permanent prostate brachytherapy (TIPPB) by obtaining data regarding current clinical practice among the most experienced TIPPB brachytherapists in the United States, Methods and Materials: The 70 brachytherapists who performed the greatest number of TIPPB cases in 1995 in the U.S. were surveyed. Each received a comprehensive four page questionnaire that included sections on training and experience, patient and isotope selection criteria, manpower, technique, and follow-up, Thirty-five (50%) surveys were ultimately returned after three mailings and follow-up phone calls, The cumulative experience of the 35 respondents represented approximately 45% of the total TIPPB volume in the U.S. for 1995, Respondents included 29 from the private sector and six from academic programs, Results: The median physician experience with TIPPB was reported as 4.9 years, Each performed an average of 73 TIPPB procedures in 1995 (range 40-300). This represented an increase in volume for most (74%) of the respondents, Sixty-three percent of the respondents attended a formal training course, 54% had TIPPB-specific residency training, and 31% had been proctored (16 had received two or more types of training experience), The most commonly reported selection criteria for implant alone was on Gleason score less than or equal to 7, PSA <15, less than or equal to Stage T2a, and gland size less than or equal to 60 cc, although no clear consensus was found. Fifty-four percent considered a history of TURF to be a relative contraindication, while 34% considered TURF to have no impact on patient selection. Eighty-six percent of respondents combine brachytherapy with external beam radiation in an average of 32% of their patients, Boosts were given with both I-125 prescribed to 120 Gy (75%) or (103)pd to 90 Gy (50%), Sixty percent reported using a Mick applicator, 46% prefer using preloaded needles, and (11%) use both techniques, Real-time imaging was usually performed with ultrasound (94%); most included fluoroscopy (60%). Definitions of PSA control varied widely, Conclusions: TIPPB clinical practice in the U.S. demonstrates similarities in technique, but differences in patient selection and definitions of biochemical control, It is, therefore, incumbent on those beginning TIPPB programs to carefully review the specific practice details of those institutions with a broad experience. (C) 1998 Elsevier Science Inc.
引用
收藏
页码:461 / 465
页数:5
相关论文
共 10 条
[1]   PROSTATE-SPECIFIC ANTIGEN BASED DISEASE-CONTROL FOLLOWING ULTRASOUND-GUIDED (125)IODINE IMPLANTATION FOR STAGE T1/T2 PROSTATIC-CARCINOMA [J].
BLASKO, JC ;
WALLNER, K ;
GRIMM, PD ;
RAGDE, H .
JOURNAL OF UROLOGY, 1995, 154 (03) :1096-1099
[2]  
Blasko John, 1996, International Journal of Radiation Oncology Biology Physics, V36, P198, DOI 10.1016/S0360-3016(97)85421-1
[3]   Pd-103 brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma [J].
Dattoli, M ;
Wallner, K ;
Sorace, R ;
Koval, J ;
Cash, J ;
Acosta, R ;
Brown, C ;
Etheridge, J ;
Binder, M ;
Brunelle, R ;
Kirwan, N ;
Sanchez, S ;
Stein, D ;
Wasserman, S .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1996, 35 (05) :875-879
[4]   TREATMENT-RELATED SYMPTOMS DURING THE 1ST YEAR FOLLOWING TRANSPERINEAL I-125 PROSTATE IMPLANTATION [J].
KLEINBERG, L ;
WALLNER, K ;
ROY, J ;
ZELEFSKY, M ;
ARTERBERY, VE ;
FUKS, Z ;
HARRISON, L .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1994, 28 (04) :985-990
[5]  
PRETE JJ, IN PRESS INT J RAD O
[6]  
Stock RG, 1996, CANCER-AM CANCER SOC, V77, P2386, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2386::AID-CNCR30>3.0.CO
[7]  
2-R
[8]   Sexual potency following interactive ultrasound-guided brachytherapy for prostate cancer [J].
Stock, RG ;
Stone, NN ;
Iannuzzi, C .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1996, 35 (02) :267-272
[9]   DOSIMETRY GUIDELINES TO MINIMIZE URETHRAL AND RECTAL MORBIDITY FOLLOWING TRANSPERINEAL I-125 PROSTATE BRACHYTHERAPY [J].
WALLNER, K ;
ROY, J ;
HARRISON, L .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 32 (02) :465-471
[10]   Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma [J].
Wallner, K ;
Roy, J ;
Harrison, L .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (02) :449-453